SEARCH

SEARCH BY CITATION

References

  • 1
    Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 1994; 24: 2939.
  • 2
    Jiranek GC, Bredfelt JE. Organ involvement: gut and hepatic manifestations. In: ClementsPJ, FurstDE, eds. Systemic Sclerosis. Baltimore: Williams & Wilkins, 1996: 453482.
  • 3
    Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001; 45: 34654.
  • 4
    Marie I, Ducrotté P, Hellot MF, Denis P, Levesque H. Outcome of small bowel motor impairment in systemic sclerosis: a prospective manometric 5-year follow-up. Rheumatology 2006; epub ahead of print.
  • 5
    Marie I, Levesque H, Ducrotté P, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 2001; 41: 187483.
  • 6
    Marie I, Levesque H, Ducrotté P, et al. Manometry of the upper intestinal tract in patients with systemic sclerosis: a prospective study. Arthritis Rheum 1998; 96: 7783.
  • 7
    Murphy JR, McNally P, Peller P, et al. Prolonged clearance is the primary abnormal reflux parameter in patients with progressive systemic sclerosis and esophagitis. Dig Dis Sci 1992; 37: 83341.
  • 8
    Sallam H, McNearney TA, Chen JDZ. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Phamacol Ther 2006; 23: 691712.
  • 9
    Sjögren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 126582.
  • 10
    Sjögren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996; 8: 56975.
  • 11
    Johnson DA, Drane WE, Curran J, et al. Pulmonary disease in progressive systemic sclerosis: a complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989; 149: 58993.
  • 12
    Bassotti G, Battaglia E, Debernardi V, et al. Esophageal dysfunction in scleroderma. Relationship with disease subsets. Arthritis Rheum 1997; 40: 22529.
  • 13
    Zamost BJ, Hirschberg J, Ippoliti AF, et al. Esophagitis in scleroderma: prevalence and risk factors. Gastroenterology 1987; 92: 4218.
  • 14
    Hendel L, Svejgaard E, Walsoe I, et al. Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole. Scand J Gastroenterol 1988; 23: 11826.
  • 15
    Subcommittee for scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 16
    Leroy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 17
    Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 12815.
  • 18
    Hurwitz AL, Duranceau A, Postlethwait RW. Esophageal dysfunction and Raynaud's phenomenon in patients with scleroderma. Dig Dis 1976; 21: 6016.
  • 19
    Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 8592.
  • 20
    Avidan B, Sonnenberg A, Schnell TG, et al. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97: 19306.
    Direct Link:
  • 21
    Sharma P, Morales TG, Bhattacharyya A, et al. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. Am J Gastroenterol 1997; 92: 20126.
  • 22
    Basilisco G, Barbera R, Molgora M, et al. Acid clearance and oesophageal sensitivity in patients with progressive systemic sclerosis. Gut 1993; 34: 148791.
  • 23
    Ling TC, Johnston BT. Esophageal investigations in connective tissue disease. Which tests are most appropriate? J Clin Gastroenterol 2001; 32: 336.
  • 24
    Bigard MA, Pelletier AL. Esophageal complications of non steroidal antiinflammatory drugs. Gastroenterol Clin Biol 2004; 28 (Suppl. 3): C58C61.
  • 25
    Cryer B. Mucosal defense and repair: role of prostaglandins in the stomach and duodenum. Gastroenterol Clin North Am 2001; 30: 87794.
  • 26
    Katzka DA, Reynolds JC, Saul SH, et al. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med 1987; 82: 4652.
  • 27
    Raj A, Jankowski J. Acid suppression and chemoprevention in Barrett's oesophagus. Dig Dis 2004; 22: 17180.
  • 28
    Hillman LC, Chiragakis L, Shabolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's esophagus. Med J Aust 2004; 180: 38791.
  • 29
    Csendes A, Smok G, Quiroz J, et al. Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol 2002; 97: 55460.
    Direct Link:
  • 30
    Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol 2001; 96: 200512.
    Direct Link:
  • 31
    Chang JT, Katzka DA. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med 2004; 164: 14828.
  • 32
    Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999; 94: 8691.
    Direct Link:
  • 33
    Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 2125.
  • 34
    Abraham SC, Singh VK, Yardley JH, Wu TT. Hyperplastic polyps of the esophagus and esophagogastric junction: histologic and clinicopathologic findings. Am J Surg 2001; 25: 11807.
  • 35
    Oguma J, Ozawa S, Omori T, et al. EMR of a hyperplastic polyp arising in ectopic gastric mucosa in the cervical esophagus: case report. Gastrointest Endosc 2001; 61: 3358.
  • 36
    Takeji H, Ueno J, Nishitani H. Ectopic gastric mucosa in the upper esophagus: prevalence and radiologic findings. AJR Am J Roentgenol 1995; 164: 9014.
  • 37
    Mion F, Lambert R, Partensky C, Cherkaoui M, Berger F. High-grade dysplasia in an adenoma of the upper esophagus developing on heterotopic gastric mucosa. Endoscopy 1996; 28: 6335.
  • 38
    Shibahara K, Haraguchi Y, Sasaki I, et al. A case of gastric hyperplastic polyp with malignant transformation. Hepatogastroenterology 2005; 52: 31921.
  • 39
    Takagi A, Ema Y, Horii S, Morishima M, Miyashi O, Kino I. Early adenocarcinoma arising from ectopic gastric mucosa in the cervical esophagus. Gastrointest Endosc 1995; 41: 16770.
  • 40
    Marie I, Hachulla E, Chérin P, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005; 53: 15565.
  • 41
    Kasapidis P, Xynos E, Mantides A, et al. Differences in manometry and 24-H ambulatory pH-metry between patients with and without endoscopic or histological esophagitis in gastroesophageal reflux disease. Am J Gastroenterol 2002; 88: 18939.
  • 42
    Hendel L, Hage E, Hendel J, et al. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992; 6: 56577.
  • 43
    Meier-Sydow J, Weiss SM, Buhl R, et al. Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Semin Respir Crit Care Med 1994; 15: 7796.
  • 44
    Tobin RW, Pope CE II, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 18048.
  • 45
    Troshinsky MB, Kane GC, Varga J, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994; 121: 610.